未经授权:在学术医疗中心评估加巴喷丁类药物处方的适应症。
UNASSIGNED:我们回顾性分析了在2019日历年期间在美国中西部的学术医学中心服用加巴喷丁(加巴喷丁或普瑞巴林)的18岁或以上的患者。患者人口学特征,加巴喷丁类药物处方的适应症,从随机样本中提取处方临床医生的专业,并将研究结果外推至整个队列.
未经批准:最初确定了总共6205种加巴喷丁类药物的处方。在随机处方样本中(n=721),加巴喷丁占89.5%,普瑞巴林占10.5%。服用加巴喷丁类药物的女性比男性多,平均±SD患者年龄为58.6±16.9岁。加巴喷丁类药物处方的前5个适应症是神经性疼痛,肌肉骨骼疼痛,不宁腿综合征,焦虑,和头痛。大多数(66.7%)的处方有大量到适度的证据,但29.0%的处方证据矛盾或证据不足.
未经授权:据我们所知,这项研究是第一个人工审查来自多个临床专业的临床记录,以确定加巴喷丁类药物处方的适应症的研究。尽管大多数处方都有适度的证据支持其使用,对于没有确凿证据支持的适应症,开具了高比例的加巴喷丁类药物处方.这表明处方者由于目前尚未完全理解的原因而倾向于使用加巴喷丁。应进一步研究临床医生在护理时对非标签加巴喷丁类药物处方的意图,以了解导致这些临床决策的因素。
UNASSIGNED: To evaluate indications for gabapentinoid prescription at an academic medical center.
UNASSIGNED: We retrospectively reviewed patients aged 18 years or older who were prescribed gabapentinoids (gabapentin or pregabalin) during the 2019 calendar year at an academic medical center in the US Midwest. Patient demographic characteristics, indications for gabapentinoid prescription, and prescribing clinician specialities were abstracted from a random sample, and the findings were extrapolated to the overall cohort.
UNASSIGNED: A total of 6205 prescriptions for gabapentinoids were initially identified. In the random sample of prescriptions (n=721), 89.5% were for gabapentin and 10.5% were for pregabalin. More women than men were prescribed gabapentinoids, and the mean ± SD patient age was 58.6±16.9 years. The top 5 indications for gabapentinoid prescriptions were neuropathic pain, musculoskeletal pain, restless legs syndrome, anxiety, and headache. A majority (66.7%) of prescriptions had substantial-to-modest evidence, but 29.0% of prescriptions had conflicting or insufficient evidence.
UNASSIGNED: To our knowledge, this study is one of the first to manually review clinical notes from multiple clinical specialities to ascertain indications for gabapentinoid prescriptions. Although most prescriptions had modest evidence to support their use, a high percentage of gabapentinoid prescriptions were issued for indications not supported by robust evidence. This suggests that prescribers are gravitating toward gabapentinoid use for reasons that are currently not fully understood. Clinician intent for off-label gabapentinoid prescriptions at the point of care should be further studied to understand the factors that lead to these clinical decisions.